Clinical Trial Update: Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Rhu-pGSN to reduce proinflammatory responses in healthy SCUBA divers experiencing decompression sickness; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompression Sickness

Drugs mentioned

• Rhu-pGSN (recombinant human plasma gelsolin)

Snippet

Sponsor: BioAegis Therapeutics Inc. | Conditions: Decompression Sickness | Phase 2 | Status: ACTIVE_NOT_RECRUITING